Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bi-224436 SCHEMBL29450566 | 1.00 | CYP3A4 (1.00) | CYP3A4PSIP1NR1I2EDNRAMAPK14 | |
| SCHEMBL13191166 | 0.93 | CYP3A4 (0.87) | CYP3A4PSIP1NR1I2EDNRAMAPK14 | |
| SCHEMBL13191540 | 0.92 | CYP3A4 (0.85) | CYP3A4PSIP1NR1I2EDNRAMAPK14 | |
| SCHEMBL12992220 | 0.92 | CYP3A4 (0.85) | CYP3A4PSIP1NR1I2MAPK14 | |
| SCHEMBL15093247 | 0.89 | CYP3A4 (0.80) | CYP3A4PSIP1NR1I2EDNRAMAPK14 | |
| SCHEMBL15093483 | 0.89 | CYP3A4 (0.80) | CYP3A4PSIP1NR1I2EDNRAMAPK14 | |
| SCHEMBL15093484 | 0.89 | CYP3A4 (0.80) | CYP3A4PSIP1NR1I2EDNRAMAPK14 | |
| SCHEMBL1699485 | 0.89 | CYP3A4 (0.80) | CYP3A4PSIP1NR1I2MAPK14 | |
| SCHEMBL1699253 | 0.89 | CYP3A4 (0.80) | CYP3A4PSIP1NR1I2MAPK14 | |
| SCHEMBL1699486 | 0.89 | CYP3A4 (0.80) | CYP3A4PSIP1NR1I2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | claimed |
| WO-2023183472-A1 | ANTIVIRAL PRODRUGS AND USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | disclosed |
| EP-2220046-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | GILEAD SCIENCES INC (US) | 2014-06-18 | — | — | EP | disclosed |
| WO-2014055603-A1 | PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR | GILEAD SCIENCES, INC. (US) | 2014-04-10 | — | — | WO | disclosed |
| WO-2014055618-A1 | SOLID STATE FORMS OF HIV INHIBITOR: HEMI-SUCCINATE OF (2S)-2-TERT-BUTOXY-2-(4-(2,3-DIHYDROPYRANO[4,3,2-DE]QUINOLIN-7-YL)-2-METHYLQUINOLIN-3-YL)ACETIC ACID) | GILEAD SCIENCES, INC. (US) | 2014-04-10 | — | — | WO | disclosed |
| US-20140094609-A1 | PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR | GILEAD SCIENCES INC (US) | 2014-04-03 | — | — | US | disclosed |
| US-20140094486-A1 | SOLID STATE FORMS OF HIV INHIBITOR | GILEAD SCIENCES INC (US) | 2014-04-03 | — | — | US | disclosed |
| US-20140094485-A1 | SOLID STATE FORMS OF HIV INHIBITOR | GILEAD SCIENCES, INC. | 2014-04-03 | — | — | US | disclosed |
| US-20140094610-A1 | PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR | GILEAD SCIENCES INC (US) | 2014-04-03 | — | — | US | disclosed |
| EP-2694160-A1 | SOLID STATE FORMS OF HIV INHIBITOR | Gilead Sciences, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2694160-A1 | SOLID STATE FORMS OF HIV INHIBITOR | Gilead Sciences, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2694479-A1 | PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR | Gilead Sciences, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2694479-A1 | PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR | Gilead Sciences, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012138670-A1 | PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR | GILEAD SCIENCES, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012138669-A1 | SOLID STATE FORMS OF HIV INHIBITOR | GILEAD SCIENCES, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012138670-A1 | PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR | GILEAD SCIENCES, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012138669-A1 | SOLID STATE FORMS OF HIV INHIBITOR | GILEAD SCIENCES, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012138669-A1 | SOLID STATE FORMS OF HIV INHIBITOR | GILEAD SCIENCES, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012138670-A1 | PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR | GILEAD SCIENCES, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140094609-A1 | PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR | NQO2, DUT, CYP51A1 | CYP3A4 49/4885PSIP1 3086/4885NR1I2 2763/4885 |
| US-20140094485-A1 | SOLID STATE FORMS OF HIV INHIBITOR | SDHA, SDHB, IDH1 | CYP3A4 426/4885PSIP1 2794/4885NR1I2 2841/4885 |
| US-20140094610-A1 | PROCESS FOR THE PREPARATION OF AN HIV INTEGRASE INHIBITOR | NQO2, IDH3B, IDH1 | CYP3A4 64/4885PSIP1 2247/4885NR1I2 3203/4885 |
| US-20140094486-A1 | SOLID STATE FORMS OF HIV INHIBITOR | ACIN1, SAMHD1, SUDS3 | CYP3A4 458/4885PSIP1 2893/4885NR1I2 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.